Statement of Retraction: Long noncoding RNA LINC00520 accelerates progression of papillary thyroid carcinoma by serving as a competing endogenous RNA of microRNA-577 to increase Sphk2 expression

No authors listed

No authors listed. Cell Cycle. 2023 Jul-Aug.

. 2023 Jul-Aug;22(14-16):1804.

doi: 10.1080/15384101.2023.2211865. Epub 2023 May 25.

No abstract available

Retraction of

Long noncoding RNA LINC00520 accelerates the progression of colorectal cancer by serving as a competing endogenous RNA of microRNA-577 to increase HSP27 expression.
Jin XH, Hong YG, Li P, Hao LQ, Chen M. Jin XH, et al. Hum Cell. 2020 Jul;33(3):683-694. doi: 10.1007/s13577-020-00336-8. Epub 2020 Mar 7. Hum Cell. 2020. PMID: 32146708
SP1-induced overexpression of LINC00520 facilitates non-small cell lung cancer progression through miR-577/CCNE2 pathway and predicts poor prognosis.
Wang JF, Xi ZN, Su HJ, Bao Z, Qiao YH. Wang JF, et al. Hum Cell. 2021 May;34(3):952-964. doi: 10.1007/s13577-021-00518-y. Epub 2021 Mar 11. Hum Cell. 2021. PMID: 33728585
Long noncoding RNA LINC00460 promotes carcinogenesis via sponging miR-613 in papillary thyroid carcinoma.
Feng L, Yang B, Tang XD. Feng L, et al. J Cell Physiol. 2019 Jul;234(7):11431-11439. doi: 10.1002/jcp.27799. Epub 2018 Nov 27. J Cell Physiol. 2019. PMID: 30478856
LINC00520: A Potential Diagnostic and Prognostic Biomarker in Cancer.
Zhang Q, Shen J, Wu Y, Ruan W, Zhu F, Duan S. Zhang Q, et al. Front Immunol. 2022 Mar 2;13:845418. doi: 10.3389/fimmu.2022.845418. eCollection 2022. Front Immunol. 2022. PMID: 35309319 Free PMC article. Review.
MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma.
Zembska A, Jawiarczyk-Przybyłowska A, Wojtczak B, Bolanowski M. Zembska A, et al. Anticancer Res. 2019 Jan;39(1):33-40. doi: 10.21873/anticanres.13077. Anticancer Res. 2019. PMID: 30591438 Review.